A phase IIb trial of Cabaletta in oculopharyngeal muscular dystrophy (OPMD)

Trial Profile

A phase IIb trial of Cabaletta in oculopharyngeal muscular dystrophy (OPMD)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Trehalose (Primary)
  • Indications Oculopharyngeal muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors Bioblast Pharma
  • Most Recent Events

    • 05 Jun 2017 According to a Bioblast pharma media release, the company has received confirmation from Health Canada for commencement of this trial.
    • 05 Jun 2017 Status changed from planning to not yet recruiting, according to a Bioblast pharma media release.
    • 01 Feb 2017 Planned initiation date changed from 1 Jul 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top